Process for the production of vaccine

Patent 4372883 Issued on February 8, 1983. Estimated Expiration Date:

August 18, 2000. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3641235

3645852

Conjugates of acid polysaccharides and complex organic substances
Patent #: 4003792
Issued on: 01/18/1977
Inventor: Mill , et al.

Immunological materials
Patent #: 4046722
Issued on: 09/06/1977
Inventor: Rowland

Chemically modified endotoxin immunizing agent
Patent #: 4057685
Issued on: 11/08/1977
Inventor: McIntire

Immunologic chemotherapeutic agents comprising antigen binding dimers covalently bound to drugs
Patent #: 4093607
Issued on: 06/06/1978
Inventor: Sela, et al.

Affinity chromatography of vibrio cholerae enterotoxin-ganglioside polysaccharide and the biological effects of ganglioside-containing soluble polymers
Patent #: 4125492
Issued on: 11/14/1978
Inventor: Cuatrecasas , et al.

Antigen-protein complex for blocking allergic reactions
Patent #: 4140679
Issued on: 02/20/1979
Inventor: Malley

ଲ-Galactosyl-umbelliferone-labeled aminoglycoside antibiotics and intermediates in their preparation Patent #: 4226978
Issued on: 10/07/1980
Inventor: Boguslaski , et al.

Inventors

Assignee

Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Application

No. 06/178904 filed on 08/18/1980

US Classes:

424/197.11, Conjugate or complex includes bacterium or component thereof or substance produced by said bacterium424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)424/193.1, Conjugate or complex424/238.1, Corynebacterium (e.g., Corynebacterium diphtheriae, etc.)424/239.1, Clostridium (e.g., Clostridium tetani, etc.)435/961, INCLUDING A STEP OF FORMING, RELEASING, OR EXPOSING THE ANTIGEN OR FORMING THE HAPTEN-IMMUNOGENIC CARRIER COMPLEX OR THE ANTIGEN, PER SE436/543, INVOLVING PRODUCING OR TREATING ANTIGEN OR HAPTEN530/389.1, Polyclonal antibody or immunogloblin of identified binding specificity530/389.5, Binds bacterium or similar microorganism or component or product thereof (e.g., Pseudomonas, Chlamydia, Clostridium, bacterium-associated antigen, etc.)530/404, Sulfur containing reactant530/406, Oxygen containing reactant530/413, Immunological separation or affinity chromatography530/806, ANTIGENIC PEPTIDES OR PROTEINS530/825, Bacteria530/826, Viruses530/856, Snakes; venom536/4.1O- or S- Glycosides

Examiners

Primary: Schain, Howard E.

Attorney, Agent or Firm

Browdy and neimark

International Classes

A61K 39/00 (20060101)
A61K 47/48 (20060101)

Foreign Application Priority Data

1979-09-05 JP

Abstract

The present invention relates to a process for the production of vaccine, characterized by covalent attachment of a biologically toxic substance to a saccharide both to form a biologically toxic substance-saccharide conjugate and to detoxify said substance, followed by collection of the formed conjugate. According to the invention, various vaccine products having a high productivity of immunoglobulin G and M antibodies, but without productivity of immunoglobulin E antibody, are easily obtainable. In addition, the vaccine products, upon administration to animals, do not effect any allergic reaction and/or anaphylactic-shock due to the lack of the immunoglobulin E antibody production.